Chemotherapy News and Research

Latest Chemotherapy News and Research

Pathologic complete response after presurgery chemotherapy increases overall survival for TNBC patients

Pathologic complete response after presurgery chemotherapy increases overall survival for TNBC patients

Capecitabine increases disease-free survival for HER2-negative breast cancer patients

Capecitabine increases disease-free survival for HER2-negative breast cancer patients

Postponing chemotherapy may increase risk of death for triple-negative breast cancer patients

Postponing chemotherapy may increase risk of death for triple-negative breast cancer patients

Lilly, Merck announce another immuno-oncology collaboration

Lilly, Merck announce another immuno-oncology collaboration

New three-drug delivery system shows promise for treatment of metastatic melanoma

New three-drug delivery system shows promise for treatment of metastatic melanoma

FDA clears for marketing first cooling cap to reduce chemotherapy-induced hair loss

FDA clears for marketing first cooling cap to reduce chemotherapy-induced hair loss

Gene may play role in protecting breast cancer patients from developing chemobrain

Gene may play role in protecting breast cancer patients from developing chemobrain

Study: Older breast cancer patients have better survival rates than what is predicted by ePrognosis tool

Study: Older breast cancer patients have better survival rates than what is predicted by ePrognosis tool

Roche announces regulatory clearance to finalize acquisition of Kapa Biosystems

Roche announces regulatory clearance to finalize acquisition of Kapa Biosystems

Web-based survey system for symptom collection benefits cancer patients

Web-based survey system for symptom collection benefits cancer patients

New Loyola Center for Cancer Care & Research opens at Palos Community Hospital

New Loyola Center for Cancer Care & Research opens at Palos Community Hospital

Pediatric chemotherapy regimen improves outcomes in young adults with ALL

Pediatric chemotherapy regimen improves outcomes in young adults with ALL

Researchers discover 'triple attack' technique to target liver cancer tumors

Researchers discover 'triple attack' technique to target liver cancer tumors

First targeted treatment to improve survival of high-risk patients with acute myeloid leukemia

First targeted treatment to improve survival of high-risk patients with acute myeloid leukemia

Researchers identify genes that act as brakes to stop development of aggressive type of leukaemia

Researchers identify genes that act as brakes to stop development of aggressive type of leukaemia

Study: Certain characteristics can lead to therapy-related leukemia in breast cancer survivors

Study: Certain characteristics can lead to therapy-related leukemia in breast cancer survivors

Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

Phase 1 BelCHOP study shows belinostat and CHOP chemo regimen as first-line treatment for PTCL

Phase 1 BelCHOP study shows belinostat and CHOP chemo regimen as first-line treatment for PTCL

Study shows promise for cord blood-derived natural killer cells in multiple myeloma patients

Study shows promise for cord blood-derived natural killer cells in multiple myeloma patients

New approaches to treating leukemia, lymphoma and myeloma

New approaches to treating leukemia, lymphoma and myeloma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.